Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Invested Capital (2020 - 2025)

Historic Invested Capital for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$8.1 million.

  • Insight Molecular Diagnostics' Invested Capital fell 17883.78% to -$8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.1 million, marking a year-over-year decrease of 17883.78%. This contributed to the annual value of -$12.0 million for FY2024, which is 15287.51% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Invested Capital of -$8.1 million as of Q3 2025, which was down 17883.78% from $1.8 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Invested Capital's 5-year high stood at $114.4 million during Q2 2021, with a 5-year trough of -$12.0 million in Q4 2024.
  • Over the past 5 years, Insight Molecular Diagnostics' median Invested Capital value was $34.4 million (recorded in 2022), while the average stood at $41.3 million.
  • Its Invested Capital has fluctuated over the past 5 years, first soared by 18647.34% in 2021, then plummeted by 17883.78% in 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Invested Capital (Quarter) stood at $66.6 million in 2021, then plummeted by 48.35% to $34.4 million in 2022, then tumbled by 33.78% to $22.8 million in 2023, then crashed by 152.88% to -$12.0 million in 2024, then soared by 32.43% to -$8.1 million in 2025.
  • Its Invested Capital stands at -$8.1 million for Q3 2025, versus $1.8 million for Q2 2025 and $10.7 million for Q1 2025.